31 articles for JL Duffy
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Cmpds
Data
Article Title
Organization
36
Discovery of Novel Indoline Cholesterol Ester Transfer Protein Inhibitors (CETP) through a Structure-Guided Approach.
Merck Research Laboratories
12
Improved Cav2.2 Channel Inhibitors through a gem-Dimethylsulfone Bioisostere Replacement of a Labile Sulfonamide.
Merck Research Laboratories
12
Aminopiperidine sulfonamide Cav2.2 channel inhibitors for the treatment of chronic pain.
Merck Research Laboratories
43
Imidazopyridines: a novel class of hNav1.7 channel blockers.
Merck Research Laboratories
22
A potent and selective indole N-type calcium channel (Ca(v)2.2) blocker for the treatment of pain.
Merck Research Laboratories
21
Discovery of a novel class of biphenyl pyrazole sodium channel blockers for treatment of neuropathic pain.
Merck Research Laboratories
46
Discovery of imidazole carboxamides as potent and selective CCK1R agonists.
Merck Research Laboratories
24
Benzazepinone Nav1.7 blockers: potential treatments for neuropathic pain.
Merck Research Laboratories
19
4-arylcyclohexylalanine analogs as potent, selective, and orally active inhibitors of dipeptidyl peptidase IV.
Merck Research Laboratories
54
Discovery of Ethyl Ketone-Based Highly Selective HDACs 1, 2, 3 Inhibitors for HIV Latency Reactivation with Minimum Cellular Potency Serum Shift and Reduced hERG Activity.
Merck
12
Discovery and investigation of a novel class of thiophene-derived antagonists of the human glucagon receptor.
Merck Research Laboratories
78
Invention of MK-8262, a Cholesteryl Ester Transfer Protein (CETP) Inhibitor Backup to Anacetrapib with Best-in-Class Properties.
Merck
32
Discovery of Highly Selective and Potent HDAC3 Inhibitors Based on a 2-Substituted Benzamide Zinc Binding Group.
Merck
27
Potent, non-covalent reversible BTK inhibitors with 8-amino-imidazo[1,5-a]pyrazine core featuring 3-position bicyclic ring substitutes.
Merck
14
Synthesis and activity of novel HIV protease inhibitors with improved potency against multiple PI-resistant viral strains.
Merck Research Laboratories
22
Cholesteryl ester transfer protein (CETP) inhibitors based on cyclic urea, bicyclic urea and bicyclic sulfamide cores.
Merck
24
Development of a selective HDAC inhibitor aimed at reactivating the HIV latent reservoir.
Merck
19
Selective Class I HDAC Inhibitors Based on Aryl Ketone Zinc Binding Induce HIV-1 Protein for Clearance.
Merck
36
Discovery of ethyl ketone-based HDACs 1, 2, and 3 selective inhibitors for HIV latency reactivation.
Merck
49
Discovery of MK-8719, a Potent O-GlcNAcase Inhibitor as a Potential Treatment for Tauopathies.
Merck
23
A novel benzazepinone sodium channel blocker with oral efficacy in a rat model of neuropathic pain.
Merck Research Laboratories
29
Optimization of Preclinical Metabolism for Somatostatin Receptor Subtype 5-Selective Antagonists.
Merck
10
Discovery and Pharmacology of a Novel Somatostatin Subtype 5 (SSTR5) Antagonist: Synergy with DPP-4 Inhibition.
Merck
4
A Dual Non-ATP Analogue Inhibitor of Aurora Kinases A and B, Derived from Resorcinol with a Mixed Mode of Inhibition.
Jawaharlal Nehru Centre For Advanced Scientific Research
14
3,4-dihydroisoquinoline compound and use thereof
CSPC Zhongqi Pharmaceutical Technology (Shijiazhuang)